NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Braze Raises Its Outlook As Results Beat Expectations

Braze exceeded Q3 earnings expectations with 25% revenue growth and raised full-year guidance, sending shares up 14% after hours as the customer engagement platform demonstrates resilient demand.

Braze Raises Its Outlook As Results Beat Expectations
Credit: Braze
Already have an account? Sign in.
12/09/2025 · 5:26 PM
BRZE
/ Don’t stop at just one post.

Related↓

Sam Altman TechCrunch Disrupt San Francisco 2019
Featured/ 09/30/2025 · 2:51 PM

AI Wars: New OpenAI Tools Challenge DocuSign and HubSpot

OpenAI introduces two major new tools, "DocuGPT" and "Tailor Assist", directly challenging the core businesses of DocuSign and HubSpot, leading to market pressure on major software companies.

/ Subscriber only
/ Read more

Feed↓

GameStop Prepares Bold Bid to Buy eBay
Featured/ 05/01/2026 · 5:42 PM

GameStop Prepares Bold Bid to Buy eBay

GameStop plans to buy eBay to grow big. CEO Ryan Cohen wants to turn it into a $100B company using its strong cash position.

/ Subscriber only
Chinese EV Stocks Slide After Weak April Deliveries – NIO Drops 7.5%
05/01/2026 · 4:37 PM

Chinese EV Stocks Slide After Weak April Deliveries – NIO Drops 7.5%

Nio, XPeng, and Li Auto saw April sales drop from March, but new SUVs and tech could help them recover in the coming months.

/ Subscriber only
FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation
05/01/2026 · 12:56 PM

FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation

FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe